HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

Development of extracellular vesicle-based medicinal products: A position paper of the group “Extracellular Vesicle translatiOn to clinicaL perspectiVEs – EVOLVE France”

Amanda K.A. Silva 1, * Marie Morille 2 Max Piffoux 3, 1 Surendar Arumugam 1 Phlippe Mauduit 3 Jérôme Larghero 4 Arnaud Bianchi 5 Kelly Aubertin 1 Olivier Blanc-Brude 6 Danièle Noël 7 Emilie Velot 5 Célia Ravel 8, 9 Céline Elie-Caille 10 Anna Sebbagh 1 Chantal Boulanger 6 Claire Wilhelm 11 Gabriel Rahmi 12 Isabelle Raymond-Letron 13 Kondareddy Cherukula 1 Tristan Montier 14 Christophe Martinaud 3 Jean-Marie Bach 15 Olivier Favre-Bulle Jolanda Spadavecchia 16 Christian Jorgensen 7 Philippe Menasché 6 Clotilde Aussel 3 Joël Chopineau 2 Mathilde Mosser 15 Matti Ullah 1 Nicolas Sailliet 17 Nathalie Luciani 1 Noëlle Mathieu 18 Pierre-Emmanuel Rautou 19 Sophie Brouard 17 Wilfrid Boireau 10 Sébastien Jauliac 4 Marianne Dedier 3 Jean-Hugues Trouvin 20 Florence Gazeau 1 Marina Trouillas 3 Juliette Peltzer 3 Antoine Monsel 21 Sébastien Banzet 3, *
Abstract : Extracellular vesicles (EV) are emergent therapeutic effectors that have reached clinical trial investigation. To translate EV-based therapeutic to clinic, the challenge is to demonstrate quality, safety, and efficacy, as required for any medicinal product. EV research translation into medicinal products is an exciting and challenging perspective. Recent papers, provide important guidance on regulatory aspects of pharmaceutical development, defining EVs for therapeutic applications and critical considerations for the development of potency tests. In addition, the ISEV Task Force on Regulatory Affairs and Clinical Use of EV-based Therapeutics as well as the Exosomes Committee from the ISCT are expected to contribute in an active way to the development of EV-based medicinal products by providing update on the scientific progress in EVs field, information to patients and expert resource network for regulatory bodies. The contribution of our work group "Extracellular Vesicle translatiOn to clinicaL perspectiVEs - EVOLVE France", created in 2020, can be positioned in complement to all these important initiatives. Based on complementary scientific, technical, and medical expertise, we provide EV-specific recommendations for manufacturing, quality control, analytics, non-clinical development, and clinical trials, according to current European legislation. We especially focus on early phase clinical trials concerning immediate needs in the field. The main contents of the investigational medicinal product dossier, marketing authorization applications, and critical guideline information are outlined for the transition from research to clinical development and ultimate market authorization.
Document type :
Journal articles
Complete list of metadata

https://hal.archives-ouvertes.fr/hal-03412034
Contributor : Marie Morille Connect in order to contact the contributor
Submitted on : Tuesday, December 14, 2021 - 3:21:58 PM
Last modification on : Friday, May 20, 2022 - 11:06:48 AM

Licence


Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Identifiers

Citation

Amanda K.A. Silva, Marie Morille, Max Piffoux, Surendar Arumugam, Phlippe Mauduit, et al.. Development of extracellular vesicle-based medicinal products: A position paper of the group “Extracellular Vesicle translatiOn to clinicaL perspectiVEs – EVOLVE France”. Advanced Drug Delivery Reviews, Elsevier, 2021, 179, pp.114001. ⟨10.1016/j.addr.2021.114001⟩. ⟨hal-03412034⟩

Share

Metrics

Record views

113

Files downloads

6